Profusa, Inc.

Profusa, Inc. is a clinical-stage digital health and medical technology company headquartered in Berkeley, California. The company's core business involves pioneering injectable hydrogel biosensors and AI-driven health management platforms. Its mission is to enable personalized healthcare through real-time biochemistry, aiming to unlock a new era of personalized, preventive, and precision medicine by continuously measuring the body's chemistry from within the tissue.

Profusa's key offering is the Lumee™ platform, which utilizes biologically compatible injectable hydrogel microsensors to continuously monitor body chemistry for extended periods. This platform includes the Lumee™ Oxygen Platform, designed for real-time tissue oxygen monitoring in conditions such as peripheral artery disease, chronic wounds, and critical limb ischemia. Additionally, the company is developing the Lumee™ Glucose Platform for long-duration continuous glucose monitoring. The technology integrates a reusable optical reader and an AI platform, powered by NVIDIA, to provide personalized clinical insights.

Profusa became publicly traded on NASDAQ under the ticker PFSA on July 14, 2025. Ben Hwang, Ph.D., serves as the Chairman and CEO. Recent strategic developments include a Letter of Intent in April 2026 to acquire the PanOmics™ multi-omics diagnostics platform, aiming to expand into precision diagnostics with an initial focus on pancreatic cancer. The company is also collaborating with Mayo Clinic to advance its oxygen monitoring technologies. Despite raising its 2026 revenue guidance following European purchase orders, Profusa faces NASDAQ listing risks due to non-compliance with market value requirements, and its auditors have expressed substantial doubt about its ability to continue as a going concern.